Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
Voyager Therapeutics Inc (NASDAQ: VYGR) closed the day trading at $4.20 down -20.96% from the previous closing price of $5.32. In other words, the price has decreased by -$20.96 from its previous closing price. On the day, 1.38 million shares were traded. VYGR stock price reached its highest trading level at $5.2 during the session, while it also had its lowest trading level at $4.125.
Ratios:
For a better understanding of VYGR, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 8.45 and its Current Ratio is at 8.45. In the meantime, Its Debt-to-Equity ratio is 0.14 whereas as Long-Term Debt/Eq ratio is at 0.12.
On December 02, 2024, Citigroup started tracking the stock assigning a Buy rating and target price of $12.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Feb 11 ’25 when Fahey Sandell Jacquelyn bought 4,358 shares for $4.45 per share.
Carter Todd Alfred bought 5,413 shares of VYGR for $24,110 on Feb 11 ’25. On Feb 11 ’25, another insider, Sandrock Alfred, who serves as the Officer of the company, bought 16,644 shares for $4.45 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, VYGR now has a Market Capitalization of 229700640 and an Enterprise Value of -70312408. As of this moment, Voyager’s Price-to-Earnings (P/E) ratio for their current fiscal year is 5.83. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.40 while its Price-to-Book (P/B) ratio in mrq is 0.69. Its current Enterprise Value per Revenue stands at -0.429 whereas that against EBITDA is -4.976.
Stock Price History:
The Beta on a monthly basis for VYGR is 0.95, which has changed by -0.27815467 over the last 52 weeks, in comparison to a change of 0.21313763 over the same period for the S&P500. Over the past 52 weeks, VYGR has reached a high of $10.66, while it has fallen to a 52-week low of $4.99. The 50-Day Moving Average of the stock is -27.09%, while the 200-Day Moving Average is calculated to be -39.90%.
Shares Statistics:
Over the past 3-months, VYGR traded about 420.50K shares per day on average, while over the past 10 days, VYGR traded about 260180 shares per day. A total of 54.54M shares are outstanding, with a floating share count of 44.97M. Insiders hold about 17.67% of the company’s shares, while institutions hold 64.45% stake in the company. Shares short for VYGR as of 1738281600 were 2605915 with a Short Ratio of 6.07, compared to 1735603200 on 2462166. Therefore, it implies a Short% of Shares Outstanding of 2605915 and a Short% of Float of 5.6900002.
Earnings Estimates
The dynamic stock of Voyager Therapeutics Inc (VYGR) is currently being evaluated by a team of 11.0 analysts, each contributing to its current rating.The consensus estimate for the next quarter is -$0.44, with high estimates of -$0.17 and low estimates of -$0.72.
Analysts are recommending an EPS of between -$0.66 and -$1.17 for the fiscal current year, implying an average EPS of -$0.91. EPS for the following year is -$1.5, with 10.0 analysts recommending between -$0.63 and -$3.08.
Revenue Estimates
12 analysts predict $16.58M in revenue for the current quarter. It ranges from a high estimate of $25M to a low estimate of $5M. As of the current estimate, Voyager Therapeutics Inc’s year-ago sales were $90.06MFor the next quarter, 12 analysts are estimating revenue of $12.95M. There is a high estimate of $31M for the next quarter, whereas the lowest estimate is $1M.
A total of 12 analysts have provided revenue estimates for VYGR’s current fiscal year. The highest revenue estimate was $98.72M, while the lowest revenue estimate was $78.7M, resulting in an average revenue estimate of $90.3M. In the same quarter a year ago, actual revenue was $250.01MBased on 12 analysts’ estimates, the company’s revenue will be $68.24M in the next fiscal year. The high estimate is $144M and the low estimate is $4M.
